Article
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.
Oncotarget - 30 Mar 2014
Killela Patrick J, Pirozzi Christopher J, Healy Patrick, Reitman Zachary J, Lipp Eric, Rasheed B Ahmed, Yang Rui, Diplas Bill H, Wang Zhaohui, Greer Paula K, Zhu Huishan, Wang Catherine Y, Carpenter Austin B, Friedman Henry, Friedman Allan H, Keir Stephen T, He Jie, He Yiping, McLendon Roger E, Herndon James E, Yan Hai, Bigner Darell D
Abstract excerpt
Frequent mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) and the promoter of telomerase reverse transcriptase (TERT) represent two significant discoveries in glioma genomics. Understanding the degree to which these two mutations co-occur or occur exclusively of one another in glioma subtypes presents a unique opportunity to guide glioma classification and prognosis. We analyzed the relationship...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.